Mutation status of refractory to imatinib patients with chronic myeloid leukemia
Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and secondary imatinib resistance was analyzed. BCR-ABL mutations identified by direct DNA sequencing. BCR-ABL kinase domain mutations were detected in 30.5 % (11 of 36) of those patients. Most of identified...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Onkogematologiâ |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/72 |
| id |
doaj-2fbfaf96e780496c9316678c41e0958c |
|---|---|
| record_format |
Article |
| spelling |
doaj-2fbfaf96e780496c9316678c41e0958c2021-07-29T09:03:04ZrusABV-pressOnkogematologiâ1818-83462014-07-0174162310.17650/1818-8346-2012-7-4-16-2387Mutation status of refractory to imatinib patients with chronic myeloid leukemiaE. G. Ovsyannikova0K. D. Kaplanov1T. Yu. Klitochenko2A. V. Misyurin3I. L. Davydkin4L. V. Zaklyakova5E. A. Popov6B. N. Levitan7Astrakhan State Medical AcademyVolgograd Regional Clinical Oncological Dispensary № 1Volgograd Regional Clinical Oncological Dispensary № 1LLC «GenoTehnologiya»Research Institute of Hematology, Transfusiology and Intensive Care, Samara State Medical University, Ministry of Health of RussiaAstrakhan State Medical AcademyAstrakhan State Medical AcademyAstrakhan State Medical AcademyMutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and secondary imatinib resistance was analyzed. BCR-ABL mutations identified by direct DNA sequencing. BCR-ABL kinase domain mutations were detected in 30.5 % (11 of 36) of those patients. Most of identified mutations were missense mutations: Q252H, M244V, G250E, Y253F/H, E255K/V, T315I, M351T, F359V, F359C, F486S. Patients with BCR-ABL mutations have significantly lower 4-year event-free survival compared with CML patients without mutations (18 % vs. 53 %; р = 0.003). The results can be used as reference information in deciding on therapy in imatinib resistant CML patients with clinically relevant BCR-ABL mutations.https://oncohematology.abvpress.ru/ongm/article/view/72chronic myeloid leukemiabcr-abl mutationsresistanceimatinib |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
E. G. Ovsyannikova K. D. Kaplanov T. Yu. Klitochenko A. V. Misyurin I. L. Davydkin L. V. Zaklyakova E. A. Popov B. N. Levitan |
| spellingShingle |
E. G. Ovsyannikova K. D. Kaplanov T. Yu. Klitochenko A. V. Misyurin I. L. Davydkin L. V. Zaklyakova E. A. Popov B. N. Levitan Mutation status of refractory to imatinib patients with chronic myeloid leukemia Onkogematologiâ chronic myeloid leukemia bcr-abl mutations resistance imatinib |
| author_facet |
E. G. Ovsyannikova K. D. Kaplanov T. Yu. Klitochenko A. V. Misyurin I. L. Davydkin L. V. Zaklyakova E. A. Popov B. N. Levitan |
| author_sort |
E. G. Ovsyannikova |
| title |
Mutation status of refractory to imatinib patients with chronic myeloid leukemia |
| title_short |
Mutation status of refractory to imatinib patients with chronic myeloid leukemia |
| title_full |
Mutation status of refractory to imatinib patients with chronic myeloid leukemia |
| title_fullStr |
Mutation status of refractory to imatinib patients with chronic myeloid leukemia |
| title_full_unstemmed |
Mutation status of refractory to imatinib patients with chronic myeloid leukemia |
| title_sort |
mutation status of refractory to imatinib patients with chronic myeloid leukemia |
| publisher |
ABV-press |
| series |
Onkogematologiâ |
| issn |
1818-8346 |
| publishDate |
2014-07-01 |
| description |
Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and secondary imatinib resistance was analyzed. BCR-ABL mutations identified by direct DNA sequencing. BCR-ABL kinase domain mutations were detected in 30.5 % (11 of 36) of those patients. Most of identified mutations were missense mutations: Q252H, M244V, G250E, Y253F/H, E255K/V, T315I, M351T, F359V, F359C, F486S. Patients with BCR-ABL mutations have significantly lower 4-year event-free survival compared with CML patients without mutations (18 % vs. 53 %; р = 0.003). The results can be used as reference information in deciding on therapy in imatinib resistant CML patients with clinically relevant BCR-ABL mutations. |
| topic |
chronic myeloid leukemia bcr-abl mutations resistance imatinib |
| url |
https://oncohematology.abvpress.ru/ongm/article/view/72 |
| work_keys_str_mv |
AT egovsyannikova mutationstatusofrefractorytoimatinibpatientswithchronicmyeloidleukemia AT kdkaplanov mutationstatusofrefractorytoimatinibpatientswithchronicmyeloidleukemia AT tyuklitochenko mutationstatusofrefractorytoimatinibpatientswithchronicmyeloidleukemia AT avmisyurin mutationstatusofrefractorytoimatinibpatientswithchronicmyeloidleukemia AT ildavydkin mutationstatusofrefractorytoimatinibpatientswithchronicmyeloidleukemia AT lvzaklyakova mutationstatusofrefractorytoimatinibpatientswithchronicmyeloidleukemia AT eapopov mutationstatusofrefractorytoimatinibpatientswithchronicmyeloidleukemia AT bnlevitan mutationstatusofrefractorytoimatinibpatientswithchronicmyeloidleukemia |
| _version_ |
1721249604276584448 |